Stock Ratings from Analyst Ratings Network

Open Main Menu Open Sidebar

BIND Therapeutics Company Profile (NASDAQ:BIND)

Consensus Ratings for BIND Therapeutics (NASDAQ:BIND) (?)
Ratings Breakdown: 2 Hold Rating(s), 2 Buy Rating(s)
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $10.85 (76.14% upside)

Analysts' Ratings History for BIND Therapeutics (NASDAQ:BIND)
Show:
DateFirmActionRatingPrice TargetDetailsShare
4/7/2015OppenheimerInitiated CoverageOutperform$14.00ViewTweet This Rating  Share This Rating on StockTwits
3/3/2015ZacksDowngradeNeutral$6.40ViewTweet This Rating  Share This Rating on StockTwits
12/19/2014Stifel NicolausLower Price TargetBuy$20.00 -> $13.00ViewTweet This Rating  Share This Rating on StockTwits
12/4/2014Credit Suisse Group AGDowngradeOutperform -> Neutral$20.00 -> $10.00ViewTweet This Rating  Share This Rating on StockTwits
8/19/2014Stifel NicolausInitiated CoverageBuy$20.00ViewTweet This Rating  Share This Rating on StockTwits
7/3/2014Credit Suisse Group AGReiterated RatingOutperform$21.00 -> $20.00ViewTweet This Rating  Share This Rating on StockTwits
10/15/2013Cowen and CompanyInitiated CoverageOutperformViewTweet This Rating  Share This Rating on StockTwits
10/15/2013JMP SecuritiesInitiated CoverageOutperform$30.00ViewTweet This Rating  Share This Rating on StockTwits
10/15/2013Stifel NicolausInitiated CoverageBuy$20.00ViewTweet This Rating  Share This Rating on StockTwits
10/15/2013Credit Suisse Group AGInitiated CoverageOutperform$21.00ViewTweet This Rating  Share This Rating on StockTwits
(Data available from 5/4/2013 forward)